Exagen Inc. Reports Fourth Quarter and Full Year 2019 Results

AVISE® Testing Revenue Drives 24% Revenue Growth March 25, 2020 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today reported financial results for the fourth quarter and full year ended December 31, 2019. Recent …

Dr. Debra Jeske Zack

Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer

SAN DIEGO, March 24, 2020 — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer (CMO), and Anja Kammesheidt, Ph.D., as Chief Scientific Officer (CSO). The addition of Drs. Zack and Kammesheidt to the Exagen team will …

Exagen Inc. Partners with Three California Medical Groups to Offer AVISE® Testing as Covered In-Network Benefit for Their Patients

Monday, March 9, 2020 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the careontinuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced three large medical groups across California have contracted with Exagen Inc. to offer AVISE testing as a covered benefit for patients …